drugset / Trial / NCT06654934
Prednisolone for 12 Versus 6 Months to Treat Pulmonary Sarcoidosis
Phase 4
Not yet recruiting
100 enrolled
Post Graduate Institute of Medical Education and Research, Chandigarh
RandomizedParallel-groupOpen-labelTreatment
Summary
In this study, the efficacy and safety of treating pulmonary sarcoidosis with 12 months vs. 6 months of prednisolone will be compared. The hypothesis is that longer treatment DURAtion would be more effective in preventing treatment failure or early relapse in SARCoidosis (DURASARC trial). The premise of this hypothesis is that even small doses of prednisolone given over longer periods can effectively suppress disease activity in sarcoidosis without a significant increase in adverse effects.
Timeline
- Start
- 2024-11
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Prednisolone | Other / unclassified | 5 mg | — |
| Comparator | Prednisolone | Other / unclassified | 10 mg | — |